Wider access to quality-assured rifapentine-based regimens is needed to accelerate tuberculosis prevention and care globally

In their correspondence, G uglielmetti et al. [1] emphasise the importance of improved access to rifapentine globally, both for the treatment of tuberculosis (TB) disease and as part of TB preventive treatment (TPT) regimens. They also highlight some of the major problems with access to this medicine, especially in the European Union (EU), foremost amongst which being the absence of market authorisation of rifapentine in the EU. In this letter we highlight key actions taken by the World Health Organization (WHO) to address important barriers to the implementation of recommendations on rifapentine. Global access to rifapentine is essential to implement the latest WHO recommendations on treatment of TB infection and disease. Measures to increase access to rifapentine include strengthening regulatory reliance practices. https://bit.ly/3xNDwID